These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31868826)

  • 21. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The many ways of osteoclast activation.
    Lorenzo J
    J Clin Invest; 2017 Jun; 127(7):2530-2532. PubMed ID: 28530641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies.
    Anandarajah AP; Schwarz EM
    Adv Exp Med Biol; 2009; 649():85-99. PubMed ID: 19731622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T; Feng X
    Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OPG/RANK/RANKL signaling system and its significance in nephrology.
    Klejna K; Naumnik B; Gasowska K; Myśliwiec M
    Folia Histochem Cytobiol; 2009; 47(2):199-206. PubMed ID: 19995704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies.
    Leibbrandt A; Penninger JM
    Adv Exp Med Biol; 2009; 649():100-13. PubMed ID: 19731623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
    Hofbauer LC; Heufelder AE
    J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts.
    Lee HL; Bae OY; Baek KH; Kwon A; Hwang HR; Qadir AS; Park HJ; Woo KM; Ryoo HM; Baek JH
    Bone; 2011 Aug; 49(2):242-9. PubMed ID: 21514407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
    Kitamura K; Takahira K; Inari M; Satoh Y; Hayakawa K; Tabuchi Y; Ogai K; Nishiuchi T; Kondo T; Mikuni-Takagaki Y; Chen W; Hattori A; Suzuki N
    Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep; 166(1):74-80. PubMed ID: 23632157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts.
    Komarova SV; Pereverzev A; Shum JW; Sims SM; Dixon SJ
    Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2643-8. PubMed ID: 15695591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
    Tsuji-Naito K
    Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoproterenol Increases RANKL Expression in a ATF4/NFATc1-Dependent Manner in Mouse Osteoblastic Cells.
    Baek K; Park HJ; Baek JH; Kim HR
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The expression of receptor activator nuclear factor-kappaB ligand and osteoprotegerin in cholesteatoma].
    Ma Y; Ye S
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Apr; 22(7):293-5. PubMed ID: 18589796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osthole inhibits osteoclasts formation and bone resorption by regulating NF-κB signaling and NFATc1 activations stimulated by RANKL.
    Ma Y; Wang L; Zheng S; Xu J; Pan Y; Tu P; Sun J; Guo Y
    J Cell Biochem; 2019 Sep; 120(9):16052-16061. PubMed ID: 31081953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the rank of RANKL in spondylarthritis?
    Loddenkemper K; Burmester GR
    Arthritis Rheum; 2008 Mar; 58(3):641-4. PubMed ID: 18311809
    [No Abstract]   [Full Text] [Related]  

  • 40. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.